To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
The global private equity firm has agreed to invest $50m in publicly-traded biopharmaceutical company Allos Therapeutics in exchange for 42 percent ownership and two seats on the board of directors.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Copyright PEI Media
Not for publication, email or dissemination